LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

Inicio・Lista de Acciones・AbCellera Biologics Inc

AbCellera Biologics Inc

Cerrado

SectorSalud

3.47 -3.61

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.41

Máximo

3.64

Métricas clave
By Trading Economics
Ingresos	48M -8.9M
Ventas	36M 45M
Margen de beneficio	-19.942
Empleados	562
EBITDA	22M -18M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+91.78% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	160M 1.1B
Apertura anterior	7.08
Cierre anterior	3.47

Noticias sobre sentimiento de mercado

By Acuity

76%

24%

326 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.99 / 2.635 Soporte y Resistencia

AbCellera Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 mar 2026, 23:12 UTC

Acciones populares

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12 mar 2026, 22:15 UTC

Ganancias

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12 mar 2026, 21:42 UTC

Noticias de Eventos Importantes

Stryker Says Cyberattack Disruption Is Continuing

12 mar 2026, 21:29 UTC

Noticias de Eventos Importantes

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12 mar 2026, 21:27 UTC

Ganancias

Adobe CEO to Depart as AI Boosts Sales -- Update

12 mar 2026, 20:46 UTC

Ganancias

Adobe Posts Higher Sales With CEO Set to Depart

12 mar 2026, 20:21 UTC

Noticias de Eventos Importantes

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12 mar 2026, 23:57 UTC

Charlas de Mercado

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12 mar 2026, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 mar 2026, 23:38 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12 mar 2026, 22:13 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

12 mar 2026, 22:13 UTC

Charlas de Mercado

Ganancias

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12 mar 2026, 21:16 UTC

Adquisiciones, fusiones, absorciones

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12 mar 2026, 21:04 UTC

Ganancias

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12 mar 2026, 21:02 UTC

Ganancias

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12 mar 2026, 21:02 UTC

Ganancias

Wheaton Precious Metals 4Q Sales $865M >WPM

12 mar 2026, 21:02 UTC

Ganancias

Wheaton Precious Metals 4Q Net $558.3M >WPM

12 mar 2026, 21:02 UTC

Ganancias

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12 mar 2026, 20:57 UTC

Charlas de Mercado

Noticias de Eventos Importantes

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

12 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12 mar 2026, 20:10 UTC

Ganancias

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12 mar 2026, 20:05 UTC

Ganancias

Adobe 1Q Rev $6.4B >ADBE

12 mar 2026, 20:05 UTC

Ganancias

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc Esperado

Precio Objetivo

By TipRanks

91.78% repunte

Estimación a 12 meses

Media 7 USD 91.78%

Máximo 7 USD

Mínimo 7 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para AbCellera Biologics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

326 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.